Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Allergic Transfusion Reaction

In brief

This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.

Key facts

Study ID

NCT04688736

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

6642

Starts

2021-01-01

Expected to finish

2027-06-30

Last updated by the study team

2025-08-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18\~65 years old.
• Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.
• Subject can fully understand and voluntarily sign informed consent forms.

You may not qualify if…

• Subject with a history of allergic diseases.
• Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
• Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.
• Subject transfused with washed RBC.
• Received allo-HSCT transplantation before.
• Subject with heart failure.
• Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.
• Pregnant or nursing women.
• Inability to understand or to follow study procedures.

Where it is running

• Zhoukou Central Hospital — Zhoukou, Henan, China (enrolling)
• The Second Affilated Hospital of Shandong First Medical University — Tai’an, Shandong, China (enrolling)
• Regenerative Medicine Center — Tianjin, Tianjin Municipality, China (enrolling)
• Anhui Provincial Hospital — Hefei, Anhui, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.